ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer

Hans U. Graber, Helmut Friess, Brigitte Kaufmann, Doris Willi, Arthur Zimmermann, Murray Korc, Markus W. Büchler

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The erbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); erbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation. Because the expression of erbB-4 mRNA is generally low in the pancreas, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine the erbB-4 levels in human normal and cancerous pancreatic tissue. Our results show that the mRNA expression of this receptor is 6-fold decreased in the nonmetastatic stages of pancreatic cancer when compared to tumors with lymph node or distant metastases or to the normal pancreas. In addition, immunohistochemistry demonstrated that in the normal pancreas, the erbB-4 antigen was predominantly present in the cell membrane and cytoplasm of the ductal and acinar cells and at a much lower level, in islet cells. In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells. Moreover, in the peri-tumorous region with chronic pancreatitis-like morphological changes, there was weak-to-moderate erbB-4 immunostaining in small ductules and degenerating acinar cells. Uni- and multivariate survival analyses using as variables age, sex, stage of cancer, histo-pathological grading, and erbB-4 immunoreactivity, revealed a significant effect for stage of cancer (p <0.01) whereby the risk of dying was 2.3 times higher in patients with metastases than in patients without. However, the level of erbB-4 immunoreactivity in pancreatic cancer cells had no influence on patient survival.

Original languageEnglish (US)
Pages (from-to)24-27
Number of pages4
JournalInternational Journal of Cancer
Volume84
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Pancreas
Messenger RNA
Acinar Cells
erbB Genes
Neoplasms
Neuregulin-1
Neoplasm Metastasis
Chronic Pancreatitis
Survival Analysis
Reverse Transcriptase Polymerase Chain Reaction
Islets of Langerhans
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Cytoplasm
Multivariate Analysis
Lymph Nodes
Immunohistochemistry
Cell Membrane
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Graber, H. U., Friess, H., Kaufmann, B., Willi, D., Zimmermann, A., Korc, M., & Büchler, M. W. (1999). ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. International Journal of Cancer, 84(1), 24-27. https://doi.org/10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2

ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. / Graber, Hans U.; Friess, Helmut; Kaufmann, Brigitte; Willi, Doris; Zimmermann, Arthur; Korc, Murray; Büchler, Markus W.

In: International Journal of Cancer, Vol. 84, No. 1, 1999, p. 24-27.

Research output: Contribution to journalArticle

Graber, HU, Friess, H, Kaufmann, B, Willi, D, Zimmermann, A, Korc, M & Büchler, MW 1999, 'ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer', International Journal of Cancer, vol. 84, no. 1, pp. 24-27. https://doi.org/10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2
Graber, Hans U. ; Friess, Helmut ; Kaufmann, Brigitte ; Willi, Doris ; Zimmermann, Arthur ; Korc, Murray ; Büchler, Markus W. / ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. In: International Journal of Cancer. 1999 ; Vol. 84, No. 1. pp. 24-27.
@article{bb03805c3a6a4f88bf311c77d667e9ed,
title = "ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer",
abstract = "The erbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); erbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation. Because the expression of erbB-4 mRNA is generally low in the pancreas, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine the erbB-4 levels in human normal and cancerous pancreatic tissue. Our results show that the mRNA expression of this receptor is 6-fold decreased in the nonmetastatic stages of pancreatic cancer when compared to tumors with lymph node or distant metastases or to the normal pancreas. In addition, immunohistochemistry demonstrated that in the normal pancreas, the erbB-4 antigen was predominantly present in the cell membrane and cytoplasm of the ductal and acinar cells and at a much lower level, in islet cells. In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells. Moreover, in the peri-tumorous region with chronic pancreatitis-like morphological changes, there was weak-to-moderate erbB-4 immunostaining in small ductules and degenerating acinar cells. Uni- and multivariate survival analyses using as variables age, sex, stage of cancer, histo-pathological grading, and erbB-4 immunoreactivity, revealed a significant effect for stage of cancer (p <0.01) whereby the risk of dying was 2.3 times higher in patients with metastases than in patients without. However, the level of erbB-4 immunoreactivity in pancreatic cancer cells had no influence on patient survival.",
author = "Graber, {Hans U.} and Helmut Friess and Brigitte Kaufmann and Doris Willi and Arthur Zimmermann and Murray Korc and B{\"u}chler, {Markus W.}",
year = "1999",
doi = "10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2",
language = "English (US)",
volume = "84",
pages = "24--27",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer

AU - Graber, Hans U.

AU - Friess, Helmut

AU - Kaufmann, Brigitte

AU - Willi, Doris

AU - Zimmermann, Arthur

AU - Korc, Murray

AU - Büchler, Markus W.

PY - 1999

Y1 - 1999

N2 - The erbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); erbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation. Because the expression of erbB-4 mRNA is generally low in the pancreas, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine the erbB-4 levels in human normal and cancerous pancreatic tissue. Our results show that the mRNA expression of this receptor is 6-fold decreased in the nonmetastatic stages of pancreatic cancer when compared to tumors with lymph node or distant metastases or to the normal pancreas. In addition, immunohistochemistry demonstrated that in the normal pancreas, the erbB-4 antigen was predominantly present in the cell membrane and cytoplasm of the ductal and acinar cells and at a much lower level, in islet cells. In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells. Moreover, in the peri-tumorous region with chronic pancreatitis-like morphological changes, there was weak-to-moderate erbB-4 immunostaining in small ductules and degenerating acinar cells. Uni- and multivariate survival analyses using as variables age, sex, stage of cancer, histo-pathological grading, and erbB-4 immunoreactivity, revealed a significant effect for stage of cancer (p <0.01) whereby the risk of dying was 2.3 times higher in patients with metastases than in patients without. However, the level of erbB-4 immunoreactivity in pancreatic cancer cells had no influence on patient survival.

AB - The erbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); erbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation. Because the expression of erbB-4 mRNA is generally low in the pancreas, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine the erbB-4 levels in human normal and cancerous pancreatic tissue. Our results show that the mRNA expression of this receptor is 6-fold decreased in the nonmetastatic stages of pancreatic cancer when compared to tumors with lymph node or distant metastases or to the normal pancreas. In addition, immunohistochemistry demonstrated that in the normal pancreas, the erbB-4 antigen was predominantly present in the cell membrane and cytoplasm of the ductal and acinar cells and at a much lower level, in islet cells. In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells. Moreover, in the peri-tumorous region with chronic pancreatitis-like morphological changes, there was weak-to-moderate erbB-4 immunostaining in small ductules and degenerating acinar cells. Uni- and multivariate survival analyses using as variables age, sex, stage of cancer, histo-pathological grading, and erbB-4 immunoreactivity, revealed a significant effect for stage of cancer (p <0.01) whereby the risk of dying was 2.3 times higher in patients with metastases than in patients without. However, the level of erbB-4 immunoreactivity in pancreatic cancer cells had no influence on patient survival.

UR - http://www.scopus.com/inward/record.url?scp=0032942803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032942803&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2

DO - 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2

M3 - Article

C2 - 9988227

AN - SCOPUS:0032942803

VL - 84

SP - 24

EP - 27

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -